Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 1, 2013, Pages 53-65

  D'Amico, Massimo ^a   Gasparoli, Luca ^a   Arcangeli, Annarosa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cancer biomarkers; Cancer therapy; Hallmarks of cancer; Ion channel pharmacology

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 AMINOPYRIDINE; AMIODARONE; ASTEMIZOLE; BUPIVACAINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CLOTRIMAZOLE; CURCUMIN; DENDROTOXIN; DEQUALINIUM; DOXAZOSIN; EDELFOSINE; ERYTHROMYCIN; IMIPRAMINE; INWARDLY RECTIFYING POTASSIUM CHANNEL; MARGATOXIN; PAXILLINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV11.1; ROSCOVITINE; SERTINDOLE; TOLBUTAMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; VERAPAMIL; VOLTAGE GATED POTASSIUM CHANNEL;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER THERAPY; CELL PROLIFERATION; CHANNEL GATING; HEART ARRHYTHMIA; HUMAN; METASTASIS; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; STRUCTURE ACTIVITY RELATION; TORSADE DES POINTES; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84875422081     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308010053     Document Type: Article

References (178)

1. Harmar AJ, Hills RA, Rosser EM, Jones M, Buneman OP, Dunbar DR, et al. IUPHAR-DB: The IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res 2009; 37 (Database issue): D680-D685.
2. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009; 8(12): 982-1001.
3. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994; 91(8): 3438-3442.
4. Nichols CG, Lopatin AN. Inward rectifier potassium channels. Annu Rev Physiol 1997; 59:171-191.
5. + channel. Neuron 1995; 14(5): 1047-1054.
6. Kofuji P, Newman EA. Potassium buffering in the central nervous system. Neuroscience 2004; 129(4): 1045-1055.
7. Neusch C, Rozengurt N, Jacobs RE, Lester HA, Kofuji P. Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination. J Neurosci 2001; 21(15): 5429-5438.
8. + channel. FEBS Lett 1999; 444(2-3): 265-269.
9. + channels by various antidepressant drugs. Neuropsychopharmacology 2004; 29(10): 1841-1851.
10. Su S, Ohno Y, Lossin C, Hibino H, Inanobe A, Kurachi Y. Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline. J Pharmacol Exp Ther 2007; 320(2):573-580.
11. Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol 2000; 279(5): F793-F801.
12. + currents: two-pore domain potassium channels. Physiol Rev 2010; 90(2): 559-605.
13. Mazella J, Pétrault O, Lucas G, Deval E, Béraud-Dufour S, Gandin C, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol 2010; 8(4): e1000355.
14. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 2005; 57(4): 463-472.
15. Tanaka Y, Aida M, Tanaka H, Shigenobu K, Toro L. Involvement of maxi-KCa channel activation in atrial natriuretic peptide-induced vasorelaxation. Naunyn Schmiedebergs Arch Pharmacol 1998; 357(6): 705-708.
16. Toro L, Wallner M, Meera P, Tanaka Y. Maxi-KCa, a unique member of the voltage-gated K channel superfamily. News Physiol Sci 1998; 13: 112-117.
17. Knaus HG, Eberhart A, Glossmann H, Munujos P, Kaczorowski GJ, Garcia ML. Pharmacology and structure of high conductance calcium-activated potassium channels. Cell Signal 1994; 6(8): 861-870.
18. + channels: From protein complexes to function. Physiol Rev 2010; 90(4): 1437-1459.
19. Ledoux J, Werner ME, Brayden JE, Nelson MT. Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 2006; 21: 69-78.
20. Garcia-Valdes J, Zamudio FZ, Toro L, Possani LD. Slotoxin, al-phaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett 2001; 505(3): 369-373.
21. + channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons. Mol Pharmacol 2006; 70(5): 1771-1782.
22. + channels stably expressed in HEK 293 cells. Br J Pharmacol 2000; 129(5): 991-999.
23. Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003; 108(9): 1119-1125.
24. + channel, IKCa1: A potential immu-nosuppressant. Proc Natl Acad Sci USA 2000; 97(14): 8151-8156.
25. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005; 57(4): 473-508.
26. Börjesson SI, Elinder F. Structure, function, and modification of the voltage sensor in voltage-gated ion channels. Cell Biochem Biophys 2008; 52(3): 149-174.
27. + channel by mutation of the H5 region. Nature 1991; 349(6311): 700-704.
28. Lu Q, Peevey J, Jow F, Monaghan MM, Mendoza G, Zhang H, et al. Disruption of KV1.1 N-type inactivation by novel small molecule inhibitors (disinactivators). Bioorg Med Chem 2008; 16(6): 3067-3075.
29. Castle NA. Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy. Expert Opin Ther Pat 2010; 20(11): 1471-1503.
30. Koo GC, Blake JT, Shah K, Staruch MJ, Dumont F, Wunderler D, et al. Correolide and derivatives are novel immunosuppressants blocking thelymphocyte KV1.3 potassium channels. Cell Immunol 1999; 197(2): 99-107
31. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Penning-ton MW, et al. KV1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006; 103(46): 17414-17419.
32. Tschritter O, Machicao F, Stefan N, Schäfer S, Weigert C, Staiger H, et al. A new variant in the human KV1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance. Clin Endo-crinol Metab 2006; 91(2): 654-658.
33. Varró A, Biliczki P, Iost N, Virág L, Hála O, Kovács P, et al. Theoretical possibilities for the development of novel antiarrhyth-mic drugs. Curr Med Chem 2004; 11(1): 1-11.
34. Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (IKur): Rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol 2008; 52(2): 105-120.
35. Zhang X, Bertaso F, Yoo JW, Baumgärtel K, Clancy SM, Lee V, et al. Deletion of the potassium channel KV12.2 causes hippocam-pal hyperexcitability and epilepsy. Nat Neurosci 2010; 13(9): 1056-1058.
36. + channels in human T lymphocytes: A role in mitogenesis? Nature 1984; 307(5950): 465-468.
37. + channels as targets for specific immunomodula-tion. Trends Pharmacol Sci 2004; 25(5): 280-289.
38. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. Targeting ion channels in cancer: A novel frontier in antineo-plastic therapy. Curr Med Chem 2009; 16(1): 66-93.
39. Arcangeli A, Pillozzi S, Becchetti A. Targeting ion channels in leukemias: A new challenge for treatment. Curr Med Chem 2012; 19(5): 683-696.
40. Olsen ML, Sontheimer H. Mislocalization of Kir channels in malignant glia. Glia 2004; 46(1): 63-73.
41. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblas-toma cell lines. Br J Cancer 2005; 93(7): 781-792.
42. Lee I, Park C, Kang WK. Knockdown of inwardly rectifying potassium channel Kir2.2 suppresses tumorigenesis by inducing reactive oxygen species-mediated cellular senescence. Mol Cancer Ther 2010; 9(11): 2951-2959.
43. Molenaar RJ. Ion Channels in Glioblastoma. International Scholarly Research Network ISRN Neurology Volume 2011, Article ID 590249, 7 pages Review Article.
44. Stringer BK, Cooper AG, Shepard SB. Overexpression of the G-protein inwardly rectifying potassium channel 1 (GIRK1) in primary breast carcinomas correlates with axillary lymph node metastasis. Cancer Res 2001; 61(2): 582-588.
45. Plummer HK, Yu Q, Cakir Y, Schuller HM. Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer 2004; 4: 93.
46. Wagner V, Stadelmeyer E, Riederer M, Regitnig P, Gorischek A, Devaney T, et al. Cloning and characterisation of GIRK1 variants resulting from alternative RNA editing of the KCNJ3 gene transcript in a human breast cancer cell line. J Cell Biochem 2010; 110(3): 598-608.
47. Takanami I, Inoue Y, Gika M. G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer. BMC Cancer 2004; 4: 79.
48. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331(6018): 768-772.
49. Plummer HK, Dhar MS, Cekanova M, Schuller HM. Expression of G-protein inwardly rectifying potassium channels (GIRKs) in lung cancer cell lines. BMC Cancer 2005; 5: 104.
50. Tan G, Sun SQ, Yuan DL. Expression of Kir 4.1 in human astro-cytic tumors: Correlation with pathologic grade. Biochem Biophys Res Commun 2008; 367(4): 743-747.
51. Higashimori H, Sontheimer H. Role of Kir 4.1 channels in growth control of glia. Glia 2007; 55: 1668-1679.
52. Huang L, Li B, Li W, Guo H, Zou F. ATP-sensitive potassium channels control glioma cells proliferation by regulating ERK activity. Carcinogenesis 2009; 30(5): 737-744.
53. Park SH, Ramachandran S, Kwon SH, Cha SD, Seo EW, Bae I, et al. Upregulation of ATP-sensitive potassium channels for estrogen-mediated cell proliferation in human uterine leiomyoma cells. Gynecol Endocrinol 2008; 24(5): 250-256.
54. +-channel subtypes in human prostate cancer. J Pharmacol Sci 2009; 109(1): 148-151.
55. Voloshyna I, Besana A, Castillo M, Matos T, Weinstein IB, Man-sukhani M, et al. TREK-1 is a novel molecular target in prostate cancer. Cancer Res 2008; 68(4): 1197-1203.
56. Ernest NJ, Logsdon NJ, McFerrin MB, Sontheimer H, Spiller SE. Biophysical properties of human medulloblastoma cells. J Membr Biol 2010; 237(2-3): 59-69.
57. + channel function. Proc Natl Acad Sci USA 2003; 100(13): 7803-7807.
58. Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, et al. Ge-nomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 2003; 3(3): 297-302.
59. Kim CJ, Cho YG, Jeong SW, Kim YS, Kim SY, Nam SW, et al. Altered expression of KCNK9 in colorectal cancers. APMIS 2004; 112(9): 588-594.
60. Meuth SG, Herrmann AM, Ip CW, Kanyshkova T, Bittner S, Wei-shaupt A, et al. The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. J Neurooncol 2008; 87(3): 263-270.
61. Pocsai K, Kosztka L, Bakondi G, Gönczi M, Fodor J, Dienes B, et al. Melanoma cells exhibit strong intracellular TASK-3-specific immunopositivity in both tissue sections and cell culture. Cell Mol Life Sci 2006; 63(19-20): 2364-2376.
62. Alvarez-Baron CP, Jonsson P, Thomas C, Dryer SE, Williams C. The two-pore domain potassium channel KCNK5: Induction by estrogen receptor alpha and role in proliferation of breast cancer cells. Mol Endocrinol 2011; 25(8): 1326-1336.
63. Arcangeli A, Wanke E, Olivotto M, Camagni S, Ferroni A. Three types of ion channels are present on the plasma membrane of Friend erythroleukemia cells. Biochem Biophys Res Commun 1987; 146(3): 1450-1457.
64. Olsen ML, Weaver AK, Ritch PS, Sontheimer H. Modulation of glioma BK channels via erbB2. J Neurosci Res 2005; 81(2): 179-189.
65. Weaver AK, Liu X, Sontheimer H. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J Neurosci Res 2004; 78(2): 224-234.
66. Gessner G, Schönherr K, Soom, M, Hansel A, Asim M, Baniahmad A, et al. BKCa channels activating at resting potential without calcium in LNCaP prostate cancer cells. J Membr Biol 2005; 208: 229-240.
67. + channels in normal and cancerous human breast. Histol Histopathol 2008; 23(8): 965-972.
68. + subpopulation of SH-SY5Y neuroblastoma cells. Bio-chem Biophys Res Commun 2010; 396(3): 637-642.
69. Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH. Calcium-activated potassium channels BK and IK1 are functionally expressed in human gliomas but do not regulate cell proliferation. PLoS One 2010; 5(8): e12304.
70. + channels in the human leukemic T cell line, Jurkat. FEBS Lett 2000; 469; 196-202.
71. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503-511.
72. Chantome A, Girault A, Potier M, Collin C, Vaudin P, Pagès JC, et al. KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res 2009; 315(20): 3620-3630.
73. Potier M, Joulin V, Roger S, Besson P, Jourdan ML, Leguennec JY, et al. Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther 2006; 5(11): 2946-2953.
74. Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, et al. The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol 2011; 162(2): 464-479.
75. Weaver AK, Bomben VC, Sontheimer H. Expression and function of calcium-activated potassium channels in human glioma cells. Glia 2006; 54(3): 223-233.
76. + channels are overexpressed in endometrial cancerand involved in regulating proliferation of endometrial cancer cells. Zhonghua Fu Chan Ke Za Zhi 2007; 42(2): 111-115.
77. + channels are expressed and functional in breast adenocarcinomas: Correlation with tumour grade and metastasis status. Histol Histopathol 2010; 25(10): 1247-1255.
78. Schmidt J, Friebel K, Schönherr R, Coppolino MG, Bosserhoff AK. Migration-associated secretion of melanoma inhibitory activity at the cell rear is supported by KCa3.1 potassium channels. Cell Res 2010; 20(11): 1224-1238.
79. Veeravalli KK, Ponnala S, Chetty C, Tsung AJ, Gujrati M, Rao JS. Integrin αx9p1-mediated cell migration in glioblastoma via SSAT and Kir4.2 potassium channel pathway. Cell Signal 2012; 24(1): 272-281.
80. Yamagishi, T., Ohshiro, H. Pyrrolopyrimidine derivatives as potassium channel modulators. WO2011018894 (2011).
81. Sørensen, U.S., Teuber, L., Peters, D., Strøbæk, D., Johansen, T.H., Nielsen, K.S., Christophersen, P. Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. US20100280087 (2010).
82. Dryer, S.E. Small peptide modulators of potassium channel trafficking. US20110086795 (2011).
83. +channels identification in human breast carcinoma cells: Involvement in cell proliferation. Biochem Biophys Res Commun 2000; 278(2): 272-277.
84. Allen ML, Koh DS, Tempel BL. Cyclic AMP regulates potassium channel expression in C6 glioma by destabilizing Kv1.1 mRNA. Proc Natl Acad Sci USA 1998; 95(13): 7693-7698.
85. Jang SH, Choi SY, Ryu PD, Lee SY. Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo. Eur J Pharmacol 2011; 651(1-3): 26-32.
86. Preussat K, Beetz C, Schrey M, Kraft R, Wölfl S, Kalff R, et al. Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas. Neurosci Lett 2003; 346(1-2): 33-36.
87. Bielanska J, Hernández-Losa J, Pérez-Verdaguer M, Moline T, Somoza R, Ramón Y Cajal S, et al. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Curr Cancer Drug Targets 2009; 9(8): 904-914.
88. Artym VV, Petty HR. Molecular proximity of Kv1.3 voltage-gated potassium channels and beta(1)-integrins on the plasma membrane of melanoma cells: Effects of cell adherence and channel blockers. J Gen Physiol 2002; 120(1): 29-37.
89. Abdul M, Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 2002; 186(1): 99-105.
90. Abdul M, Hoosein N. Reduced KV1.3 potassium channel expression in human prostate cancer. J Membr Biol 2006; 214(2): 99-102.
91. Ousingsawat J, Spitzner M, Puntheeranurak S, Terracciano L, Tornillo L, Bubendorf L, et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res 2007; 13(3): 824-831.
92. + channels support proliferation of colonic carcinoma cells. FASEB J 2007; 21(1): 35-44.
93. Abdul M, Santo A, Hoosein N. Activity of potassium channel-blockers in breast cancer. Anticancer Res 2003; 23: 3347-3351.
94. Jang SH, Kang KS, Ryu PD, Lee SY. Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. BMB Rep 2009; 42(8): 535-539.
95. Lan M, Shi Y, Han Z, Hao Z, Pan Y, Liu N, et al. Expression of delayed rectifier potassium channels and their possible roles in proliferation of human gastric cancer cells. Cancer Biol Ther 2005; 4(12): 1342-1347.
96. + channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention. Curr Med Chem 2012; 19(5): 661-674.
97. Smid, P., Mlinaric, M., Lange, J.H.M., Koehler, K.F., Nunez-Garcia, S., Wegener, E. Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers. WO2010066840 (2010).
98. Chang KW, Yuan TC, Fang KP, Yang FS, Liu CJ, Chang CS, et al. The increase of voltage-gated potassium channel Kv3.4 mRNA expression in oral squamous cell carcinoma. J Oral Pathol Med 2003; 32(10): 606-611.
99. Menéndez ST, Rodrigo JP, Allonca E, García-Carracedo D, Alva-rez-Alija G, Casado-Zapico S, et al. Expression and clinical significance of the Kv3.4 potassium channel subunit in the development and progression of head and neck squamous cell carcinomas. J Pathol 2010; 221(4): 402-410.
100. Friederich P, Benzenberg D, Urban BW. Bupivacaine inhibits human neuronal Kv3 channels in SH-SY5Y human neuroblastoma cells. Br J Anaesth 2002; 88(6): 864-866.
101. Patt S, Preussat K, Beetz C, Kraft R, Schrey M, Kalff R, et al. Expression of ether á go-go potassium channels in human gliomas. Neurosci Lett 2004; 368(3): 249-253.
102. + channel. Receptors Channels 2001; 7(5): 345-356.
103. Meyer R, Schönherr R, Gavrilova-Ruch O, Wohlrab W, Heine-mann SH. Identification of ether à go-go and calcium-activated potassium channels in human melanoma cells. J Membr Biol 1999; 171(2): 107-115.
104. Meyer R, Heinemann SH. Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 1998; 508 (PT. 1): 49-56.
105. Alfaro-Mora YE, Diaz-Chavez J, Dante-Escobedo M, Herrera LA, Camacho J. Human Eag1 potassium channel expression in lung cancer biopsies. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011; 10(SUPPL. 11): Abstract nr C13.
106. Farias LM, Ocaña DB, Díaz L, Larrea F, Avila-Chávez E, Cadena A, et al. Ether a go-go potassium channels as human cervical cancer markers. Cancer Res 2004; 64(19): 6996-7001.
107. Ortiz CS, Montante-Montes D, Saqui-Salces M, Hinojosa LM, Gamboa-Dominguez A, Hernández-Gallegos E, et al. Eag1 potassium channels as markers of cervical dysplasia. Oncol Rep 2011; 26(6): 1377-1383.
108. Mello de Queiroz F, Suarez-Kurtz G, Stühmer W, Pardo LA. Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006; 5: 42.
109. Asher V, Warren A, Shaw R, Sowter H, Bali A, Khan R. The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line. Cancer Cell Int 2011; 11: 6.
110. Ding XW, Wang XG, Luo HS, Tan SY, Gao S, Luo B, et al. Expression and prognostic roles of Eag1 in resected esophageal squamous cell carcinomas. Dig Dis Sci 2008; 53(8): 2039-2044.
111. Agarwal JR, Griesinger F, Stühmer W, Pardo LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer 2010; 9: 18.
112. Wadhwa S, Wadhwa P, Dinda AK, Gupta NP. Differential expression of potassium ion channels in human renal cell carcinoma. Int Urol Nephrol 2009; 41(2): 251-257.
113. Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gym-nopoulos M, Weber C, et al. Eag1 expression interferes with hy-poxia homeostasis and induces angiogenesis in tumors. J Biol Chem 2008; 283 (52): 36234-36240.
114. Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 2002; 16(9): 1791-1798.
115. Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by HERG1 blockers. Blood 2011; 117(3): 902-914.
116. + channel function in the human mammary carcinoma cell line MCF-7. Oncol Rep 2008; 19(6): 1511-1516.
117. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, et al. HERG1 gene and HERG1 protein are overexpressed in co-lorectal cancers and regulate cell invasion of tumor cells. Cancer Res 2004; 64(2): 606-611.
118. Meyer R, Heinemann SH. Characterization of an Eag-like potassium channel in human neuroblastoma cells. J Physiol 1998; 508 (PT. 1): 49-56.
119. Afrasiabi E, Hietamäki M, Viitanen T, Sukumaran P, Bergelin N, Törnquist K. Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration. Cell Signal 2010; 22(1): 57-64.
120. + current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells? Cancer Res 1998; 58(4): 815-822.
121. Crociani O, Guasti L, Balzi M, Becchetti A, Wanke E, Olivotto M, et al. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 2003; 278(5): 2947-2955.
122. + channels in neoplastic hematopoietic cells. J Biol Chem 2002; 277(21): 18528-18534.
123. + channel expression-related chemosensitivity in cancer cells and its modulation by erythromy-cin. Cancer Chemother Pharmacol 2005; 56(2): 212-220.
124. Banderali U, Belke D, Singh A, Jayanthan A, Giles WR, Narendran A. Curcumin blocks Kv11.1 (erg) potassium current and slows proliferation in the infant acute monocytic leukemia cell line THP-1. Cell Physiol Biochem 2011; 28(6): 1169-1180.
125. + channels. Eur J Pharmacol 2008; 579(1-3): 98-103.
126. + channel. Eur J Neurosci 2002; 16(3): 415-428.
127. Stuhmer, W., Knotgen, H., Gomez-Varela, D., Pardo, L.A., Rothe, M., Zwick-Wallasch, E., Dehne, K. Novel Antibodies directed to the mammalian EAG1 ion channel protein. US7910100 (2011).
128. + ion channel and therapeutic applications thereof. US7364730 (2008).
129. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 2007; 67(15): 7343-7349.
130. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-674.
131. Stühmer W, Pardo LA. K(+) channels as therapeutic targets in oncology. Future Med Chem 2010; 2(5): 745-755.
132. Prevarskaya N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. Trends Mol Med 2010; 16(3): 107-121.
133. Kunzelmann K. Ion channels and cancer. J Membr Biol 2005; 205(3): 159-173.
134. + current with a cell-cycle dependence governs the resting potential of mammalian neu-roblastoma cells. J Physiol 1995; 489 (PT. 2): 455-471.
135. Arcangeli A, Becchetti A. Complex functional interaction between integrin receptors and ion channels. Trends Cell Biol 2006; 16(12): 631-639.
136. + channel-mediated tumor cell proliferation and apoptosis. Apoptosis 2007; 12(10): 1837-1846.
137. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407(6805): 770-776.
138. Arcangeli A, Yuan JX. American Journal of Physiology-Cell Physiology theme: Ion channels and transporters in cancer. Am J Physiol Cell Physiol 2011; 301(2): C253-C254.
139. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angi-ogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 1995; 92(5): 1307-1311.
140. Sontheimer H. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood) 2008; 233(7): 779-791.
141. + channel for a macromolecular signaling complex in acute myeloid leukemia: Role in cell migration and clinical outcome. Blood 2007; 110(4): 1238-1250.
142. Becchetti A, Pillozzi S, Morini R, Nesti E, Arcangeli A. New insights into the regulation of ion channels by integrins. Int Rev Cell Mol Biol 2010; 279: 135-190.
143. Kubo Y, Baldwin TJ, Jan YN, Jan LY. Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 1993; 362(6416): 127-133.
144. Colden-Stanfield M. Clustering of very late antigen-4 integrins modulates K(+) currents to alter Ca(2+)-mediated monocyte function. Am J Physiol Cell Physiol 2002; 283(3): C990-C1000.
145. + channels. Adv Exp Med Biol 2010; 674: 81-94.
146. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S. Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med 1984; 160(2): 369-385.
147. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev 2009; 231(1): 59-87.
148. Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 2003; 6(5): 640-647.
149. Foran JM. New prognostic markers in acute myeloid leukemia: Perspective from the clinic. Hematology Am Soc Hematol Educ Program 2010; 47-55.
150. 2+ channel expression. Biochem Biophys Res Commun 2004; 322(4): 1359-1363.
151. Lastraioli E, Bencini L, Bianchini E, Romoli MR, Crociani O, Giommoni E, et al. HERG1 channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: A pilot study. Trans Oncol 2012; 5: 105-112.
152. Arcangeli, A., Becchetti, A., Pillozzi, S., Masselli, M., De Lorenzo, E. Method and Kit for the prevention and/or the monitoring of chemioresistance of leukemia forms. WO2011058509 (2011).
153. Arcangeli, A., Becchetti, A., Pillozzi, S., Masselli, M., De Lorenzo, E. New composition for the treatment of chemioresistant and/or potentially chemioresistant leukemias. WO20110585058 (2011).
154. Dolderer, J.H. Diagnostic agent and method for detection of cancer and a means for treatment of same. US7915294 (2011).
155. Dolderer JH, Schuldes H, Bockhorn H, Altmannsberger M, Lam-bers C, von Zabern D, et al. HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol 2010; 36(1): 72-77.
156. Masselli M, Laise P, Pillozzi S, Cetica V, Da Ros M, Sardi I, et al. Deregulation of ion channel and transporter encoding genes in paediatric gliomas. Front Oncol 2012; 2: 53.
157. Arcangeli A, Becchetti A. New trends in cancer therapy: Targeting ion channels and transporters. Pharmaceuticals 2010; 3: 1202-1224.
158. Sanguinetti MC, Tristani-Firouzi M. HERG potassium channels and cardiac arrhythmia. Nature 2006; 440(7083): 463-469.
159. Witchel HJ, Hancox JC. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 2000; 27(10): 753-766.
160. Mitcheson JS. HERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol 2008; 21(5):1005-1010.
161. Jehle J, Schweizer PA, Katus HA, Thomas D. Novel roles for HERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis 2011; 2: e193.
162. Wallis RM. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 2010; 159: 115-121.
163. Shah RR. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 2005; 266: 251-280.
164. Ganapathi SB, Kester M, Elmslie KS. State-dependent block of HERG potassium channels by R-roscovitine: Implications for cancer therapy. Am J Physiol Cell Physiol 2009; 296(4): C701-C710.
165. + channels. Eur J Neurosci 1999; 11(3): 753-760.
166. Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC, et al. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 2003; 547(1-3): 20-26.
167. Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, Tseng GN. BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J 2003; 84(5): 3022-3036.
168. + channels in the central nervous system. Mol Pharmacol 2006; 69(5): 1673-1683.
169. Wanke E, Restano-Cassulini R. Toxins interacting with ether-à-go-go-related gene voltage-dependent potassium channels. Toxicon 2007; 49(2): 239-248.
170. + channels in microglia. J Gen Physiol 1998; 111(6): 781-794.
171. Klionsky L, Tamir R, Holzinger B, Bi X, Talvenheimo J, Kim H, et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J Pharmacol Exp Ther 2006; 319(1): 192-198.
172. Hartung F, Stühmer W, Pardo LA. Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. Mol Cancer 2011; 10: 109.
173. Arcangeli A, Pillozzi S, Becchetti A. Ion Channels: Novel Functional Hubs in Leukemia. In: Ozdemir O, Eds. Current Cancer Treatment - Novel Beyond Conventional Approaches. InTech C&S, Inc. 2011.
174. Correale P, Caraglia M, Procopio A, Marinetti M, Guarrasi R, Fabbrocini A, et al. Transmembrane ion flux modifiers verapamil and ouabain modulate cytotoxic effects of extracellular ATP on human tumor-cells in vitro. Int J Oncol 1993; 3(5): 847-851.
175. Tagliaferri P, Correale P, Mottola M, Desimone G, Rea A, Ascione R, et al. Cardiovascular monitoring of drug-resistant lymphoma patients treated with epoch chemotherapy plus high-dose verapamil in continuous-infusion. Oncol Rep 1994; 1(2): 341-344.
176. Tagliaferri P, Correale P, Mottola M, de Simone G, Montesarchio V, Matano E, et al. High-dose recombinant interleukin-2/verapamil combination in advanced cancer. Eur J Cancer 1996; 32A(8): 1436-1437.
177. Correale P, Tagliaferri P, Guarrasi R, Caraglia M, Giuliano M, Marinetti MR, et al. Extracellular adenosine 5' triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. Immunol Lett 1997; 55(2): 69-78.
178. Casale F, D'Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R, et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004; 12(6): 1201.